Physician profile
Caitlin Aday
NPI 1811424732
$3,288.50
in general payments reported to CMS, 2019-2025
29 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $620 · 2022: $867 · 2023: $507 · 2024: $974 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,035.17 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $355.74 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $250.48 | 2021-2025 | |
| Daiichi Sankyo INC. | $210.87 | 2024-2025 | Injectafer |
| Abbott Laboratories | $161.16 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $150.20 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $143.83 | 2021-2023 | Trintellix |
| Novo Nordisk INC | $143.10 | 2021-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company Ltd. | $109.20 | 2022 | |
| Amgen INC. | $89.78 | 2024 | Prolia, Evenity, Repatha |
| Merck Sharp & Dohme LLC | $80.17 | 2021-2024 | Gardasil 9, Gardasil, Vaxelis |
| Astrazeneca Pharmaceuticals Lp | $65.80 | 2021-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.86 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $52.71 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $46.37 | 2022-2024 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $44.08 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Astellas Pharma US INC | $37.46 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $33.27 | 2022-2023 | |
| Antares Pharma, INC. | $32.06 | 2021-2022 | |
| Genentech USA, INC. | $30.99 | 2021 | |
| Inspire Medical Systems, INC. | $25.34 | 2024 | Inspire |
| Corcept Therapeutics | $24.59 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $23.00 | 2025 | Zoryve |
| Dynavax Technologies Corporation | $14.71 | 2022 | |
| Dexcom, INC. | $14.46 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.32 | 2025 | Xifaxan |
| Exact Sciences Corporation | $14.26 | 2023 | Cologuard Collection Kit |
| Althera Pharmaceuticals LLC | $11.86 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Aday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.